Letrozole
Liposarcoma
PfizerSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Liposarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT Pfizer | Phase 2 | B |
MIDAZOLAM Pfizer | Phase 2 | CCC |
Enzalutamide Pfizer | Phase 2 | CCC |
Atirmociclib Pfizer | Phase 2 | CCC |
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER OncoResponse, Inc. | Phase 1/2 | CC |
View all 19 →
Same molecule, other indications
Letrozole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →